Atlas Trials

A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Clinical trial NCT05665192 · COMPLETED

Trial details

NCT number
NCT05665192
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Study type
OBSERVATIONAL
Myelofibrosis
Start date
2021-08-02
Primary completion
2023-07-24
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.